Sentence examples for challenge in demonstrating from inspiring English sources

One challenge in demonstrating the gravity of the problem to the public is the lack of national standards about what level of contamination constitutes a hazard.

Women, Ms. Gorlin said, face a challenge in demonstrating "toughness," so as to overcome doubts that they can "make the cuts to balance the budget that would put people out of work, or cut day care," or "pull the switch on a convicted killer".

There is a fundamental challenge in demonstrating the utility of a ubiquitous interoperable PCHR before the environment supports either ubiquity or wide-scale interoperability.

To the former question, our experience is that internal candidates face some common challenges in demonstrating their potential as leaders.

The number of publications demonstrating fluorescent nanotechnology with smartphone sensing also showed a similar trend slow increase followed by a decrease in 2017 (Fig. 1; yellow line), suggesting complications and challenges in demonstrating fluorescent nanotechnology with smartphone sensing.

Challenges in demonstrating interchangeability and safety, as well as the ongoing evolution of regulations governing biosimilars, have meant that the development of the biosimilars industry has not been, and will not be, a carbon copy of the generics industry.

These new vaccine technologies coupled with novel adjuvants, delivery systems, formulations, dosing routes and regimes present many unique and difficult challenges in demonstrating product safety and efficacy to support clinical testing.

Developers face challenges in demonstrating that new drugs are as safe as established agents.

When reviewing fundamental research programs using the PART guidance, managers of these programs face significant challenges in demonstrating a link between traditional research outputs and outcomes (Cozzens 1997).

The debate surrounding the acceptance of progression-free survival (PFS) as an intermediate endpoint to overall survival (OS) has grown in recent years, due to the challenges in demonstrating an OS benefit within clinical trials today.

A further challenge lies in demonstrating the impact of an intervention on HCV transmission: the prevalence of HCV in IDU populations is generally high, therefore identifying a large cohort of HCV naïve IDU to prospectively study, and ensuring low rates of attrition, can be difficult.